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Abstract 
 
Alzheimer’s disease is a progressive neurodegenerative disease characterised by the accumulation of 
amyloid-β (Aβ) in the brain. Aβ oligomers are believed to cause synapse damage resulting in the 
memory deficits that are characteristic of this disease. Since the loss of synaptic proteins in the brain 
correlates closely with the degree of dementia in Alzheimer’s disease, the process of Aβ-induced 
synapse damage was investigated in cultured neurons by measuring the loss of synaptic proteins. 
Soluble Aβ oligomers, derived from Alzheimer’s-affected brains, caused the loss of cysteine string 
protein and synaptophysin from neurons. When applied to synaptosomes Aβ oligomers increased 
cholesterol concentrations and caused aberrant activation of cytoplasmic phospholipase A2 (cPLA2). In 
contrast, Aβ monomer preparations did not affect cholesterol concentrations or activate synaptic cPLA2, 
nor did they damage synapses. The Aβ oligomer-induced aggregation of cellular prion proteins (PrPC) 
at synapses triggered the activation of cPLA2 that leads to synapse degeneration. Critically, Aβ 
monomer preparations did not cause the aggregation of PrPC; rather they reduced the Aβ oligomer-
induced aggregation of PrPC. The presence of Aβ monomer preparations also inhibited the Aβ oligomer-
induced increase in cholesterol concentrations and activation of cPLA2 in synaptosomes and protected 
neurons against the Aβ oligomer-induced synapse damage. These results support the hypothesis that 
Aβ monomers are neuroprotective. We hypothesise that synapse damage may result from a pathological 
Aβ monomer:oligomer ratio rather than the total concentrations of Aβ within the brain. 
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cellular prion protein (PrPC), cytoplasmic phospholipase A2 (cPLA2), cysteine-string protein (CSP), 
enzyme-linked immunoassay (ELISA), fragment antigen-binding (Fab), glycosylphosphatidylinositol 
(GPI), monoclonal antibody (mAb), phospholipase A2-activating peptide (PLAP), prostaglandin (PG), 
sodium dodecyl sulphate (SDS), standard deviation (SD), vesicle-associated membrane protein 
(VAMP). 
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Introduction 
 
Alzheimer's disease (AD) is a complex neurological disorder characterized by a progressive dementia 
resulting from synapse failure (Selkoe, 2002; Tanzi, 2005). The amyloid hypothesis maintains that the 
pivotal event in AD is the production of amyloid-β (Aβ) peptides following the proteolytic cleavage of 
the amyloid precursor protein (APP) (De Strooper et al., 2010; Hardy and Selkoe, 2002). The 
accumulation of C-terminal fragments (Aβ) within the brain is thought to cause the synapse dysfunction 
and the memory loss that is characteristic of AD. Aβ has the capacity to self-aggregate, and 
consequently is found in different forms ranging from monomers and small soluble oligomers to much 
larger fibrils and plaques. The soluble Aβ oligomers are currently considered to be the principal 
mediators of synapse damage (Yang et al., 2017).   
 
The mechanisms of Alzheimer’s-related synapse damage can be examined by incubation of cultured 
neurons with Aβ. Since the loss of synapses and synaptic proteins is a feature of AD that strongly 
correlates with cognitive decline in AD (Counts et al., 2006; Masliah et al., 1991; Reddy et al., 2005) 
synapse density was measured by determining the amounts of synaptophysin and cysteine string protein 
(CSP) in cultured neurons (Lipton et al., 2001). Soluble forms of Aβ derived from the brains 
Alzheimer’s patients caused synapse degeneration in neurons (Yang et al., 2017). The biological effects 
of these Aβ oligomers occurred at picomolar concentrations, similar concentrations to those found in 
the cerebrospinal fluid of Alzheimer’s patients (Bibl et al., 2007; McLean et al., 1999; Mehta et al., 
2000). The role of Aβ monomers that are found in high concentrations in the brain are poorly 
understood; while some studies report that Aβ monomers are not toxic (Shankar et al., 2007; Walsh et 
al., 2002) another study suggested that they were neuroprotective (Giuffrida et al., 2009). Confusion 
may arise due to the heterogeneity of Aβ in monomer preparations, in addition to Aβ40 and Aβ42 peptides 
there are other APP fragments in cerebrospinal fluid (Brinkmalm et al., 2012) and that some of these 
carboxy-terminal fragments of APP have biological activity (Willem et al., 2015). In the present study 
Aβ monomer preparations and Aβ oligomers were isolated from soluble brain extracts and their 
biological activity studied.  
 
Increasing evidence suggests that aberrant activation of cytoplasmic phospholipase A2 (cPLA2) plays 
an important role in Aβ oligomer-induced synapse damage. For example, Aβ activates cPLA2 (Anfuso 
et al., 2004; Shelat et al., 2008) and pharmacological inhibition of cPLA2 protects cultured neurons 
against Aβ-induced synapse damage (Bate et al., 2010). In addition, cPLA2 inhibitors ameliorated 
cognitive decline in a mouse model of AD (Sanchez-Mejia et al., 2008). Here we demonstrate that 
whereas Aβ oligomers increased synaptic cholesterol concentrations, activated cPLA2 and caused 
synapse damage in cultured neurons, Aβ monomers had none of those effects. The cellular prion protein 
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(PrPC) mediates Aβ-induced memory defects (Lauren et al., 2009) and aggregation of PrPC by Aβ 
oligomers caused the activation of cPLA2 and synapse damage (Bate and Williams, 2011). Here we 
report that Aβ monomers did not cause aggregation of PrPC; rather that they reduced the aggregation of 
PrPC by Aβ oligomers. The presence of Aβ monomers significantly reduced the Aβ oligomer-induced 
activation of cPLA2 and synapse damage.  
 
Materials and Methods 
 
Primary neuronal cultures - Cortical neurons were prepared from the brains of day 15.5 mouse 
embryos as described (Bate et al., 2010). Cells were suspended in Ham’s F12 medium containing 5% 
foetal calf serum and seeded at 2 x 105 cells/well in 48 well plates that had been coated with poly-L-
lysine. After 2 hours, cultures were shaken and washed to remove non-adherent cells. Neurons were 
grown in neurobasal medium containing B27 components and 5 ng/ml nerve growth factor (Sigma) for 
10 days. Immunohistochemistry revealed that approximately 95% of cells were neurofilament positive. 
All experiments were performed in accordance with European regulations (European Community 
Council Directive, 1986, 56/609/EEC) and approved by the local authority veterinary service/ethical 
committee. To determine cell viability they were incubated with 50 µM thiazolyl blue tetrazolium 
bromide for 3 hours at 37oC. The supernatant was removed, the formazan product solubilized in 200 μl 
of dimethyl sulfoxide, transferred to an immunoassay plate and absorbance read at 595 nm. Cell survival 
was calculated with reference to untreated cells (100% survival). Neurons were incubated with Aβ 
preparations for 24 hours. For other studies, neurons were pre-treated with Aβ monomers or control 
medium for 1 hour and then incubated with Aβ oligomers or a phospholipase A2-activating protein 
(PLAP) (Bachem) for 24 hours. Treated neurons were washed 3 times with PBS and homogenised in 
150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 10 mM EDTA, Nonidet P-40, 0.5% sodium deoxycholate and 
0.2% SDS at 106 cells/ml. Mixed protease inhibitors (4-(2-Aminoethyl) benzenesulfonyl fluoride 
hydrochloride, Aprotinin, Leupeptin, Bestatin, Pepstatin A and E-46) and a phosphatase inhibitor 
cocktail including PP1, PP2A, microcystin LR, cantharidin and p-bromotetramisole (Sigma) were 
added and nuclei and large fragments were removed by centrifugation (1000 x g for 5 minutes). 
 
Western Blotting - Samples were mixed with Laemmli buffer containing β-mercaptoethanol, heated 
to 95oC for 5 minutes and proteins were separated by electrophoresis on 15% polyacrylamide gels. 
Proteins were transferred onto a Hybond-P polyvinylidiene fluoride membrane by semi-dry blotting. 
Membranes were blocked using 10% milk powder; synapsin-1 was detected with goat polyclonal (Santa 
Crux Biotech), synaptophysin with MAB368 (Abcam), cysteine-string protein (CSP), with rabbit 
polyclonal anti-CSP ((sc-33154) Santa Cruz), vesicle-associated membrane protein (VAMP)-1 with 
monoclonal antibody (mAb) 4H302 (Abcam), caveolin with rabbit polyclonal antibodies to caveolin 
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(Upstate). These were visualised using a combination of biotinylated anti-mouse/goat/rat/rabbit IgG 
(Sigma), extravidin-peroxidase and enhanced chemiluminescence.  
Synaptophysin ELISA – The amount of synaptophysin in samples was determined by ELISA as 
described (Bate et al., 2010). Maxisorb immunoplates (Nunc) were coated with an anti-synaptophysin 
mAb (MAB368-Chemicon) and blocked with 5% milk powder. Samples were added for 1 hour and 
bound synaptophysin was detected using rabbit polyclonal anti-synaptophysin (Abcam) followed by a 
biotinylated anti-rabbit IgG (Sigma), extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenol 
phosphate solution (Sigma). Absorbance was measured at 405 nm. Samples were expressed as “units 
synaptophysin” where 100 units was the amount of synaptophysin in 106 untreated cells.  
CSP ELISA – Maxisorb immunoplates were coated with a mouse mAb to CSP ((sc-136468) Santa 
Cruz) and blocked with 5% milk powder. Samples were added for 1 hour and bound CSP was detected 
using rabbit polyclonal anti-CSP ((sc-33154) Santa Cruz) followed by a biotinylated anti-rabbit IgG, 
extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenol phosphate solution. Absorbance was 
measured at 405 nm. Samples were expressed as “units CSP” where 100 units was the amount of CSP 
in 106 untreated cells.  
Isolation of synaptosomes - Synaptosomes were prepared from mouse cortical neuronal cultures, as 
described above, on a discontinuous Percoll gradient as described (Dunkley et al., 2008). Neurons were 
homogenized at 4°C in 1 ml of SED solution (0.32 M sucrose, 5 mM Tris-HCl pH 7.2, 1 mM EDTA, 
and 0.25 mM dithiothreitol) and centrifuged at 1000 x g at 4°C. The supernatant was transferred to a 4-
step gradient of 3, 7, 15, and 23% Percoll in SED solution and centrifuged at 16,000 × g for 30 minutes 
at 4oC. The synaptosomes were collected from the interface between the 15% and 23% Percoll and 
washed (16,000 × g for 10 minutes at 4oC) and suspended in neurobasal medium containing B27 
components at a concentration equivalent to 5 x 106 neurons per ml. All synaptosomes were used on 
the same day of preparation. Synaptosomes were incubated with Aβ monomers or Aβ oligomers for 1 
hour at 37oC. In one experiment synaptosomes were pre-treated with Aβ monomers for 30 minutes and 
then incubated with Aβ oligomers for 1 hour at 37oC. Treated synaptosomes were washed with ice cold 
PBS and suspended in ice cold extraction buffer (150 mM NaCl, 10 mM Tris-HCl pH 7.4, 10 mM 
EDTA, 0.2% SDS and mixed protease/phosphatase inhibitors (as above)). 
 
Synaptic vesicle recycling - The fluorescent dye FM1-43 that is taken up into synaptic recycling 
vesicles was used as an indicator of synaptic activity (Parodi et al., 2010). Treated synaptosomes were 
pulsed with 5 μM FM1-43 and 1 μM ionomycin, a calcium ionophore used to stimulate neurotransmitter 
release, for 5 minutes, washed 5 times in ice cold PBS and homogenised in methanol. Soluble extracts 
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were transferred into Sterilin 96 well black microplates and fluorescence was measured using excitation 
at 480 nm and emission at 625 nm. Samples were expressed as “% fluorescence” where 100% 
fluorescence was the fluorescence of 106 control synaptosomes pulsed with FM1-43 and ionomycin.   
 
Cholesterol content - The concentrations of cholesterol in samples were measured using the Amplex 
Red cholesterol assay kit (Life Technologies) (Robinet et al., 2010). Briefly, control and treated 
synaptosomes were washed (400 × g, 10 min) and homogenized in 500 μL isopropanol:NP40 (9:1, v/v) 
and sonicated in a waterbath (30 minutes). Samples were centrifuged (10,000 × g, 1 min); the 
supernatants pre-treated with catalase before the enzyme cocktail of the Amplex-red kit was added (0.1 
M potassium phosphate buffer, pH 7.4; 0.25 M NaCl, 5 mM cholic acid, 0.1% Triton X-100, cholesterol 
oxidase, horse radish peroxidase and 0.4 mM 10-acetyl-3,7-dihydroxyphenoxazine (± cholesterol 
esterase)) were added and incubated at 37°C for 30 minutes. Cholesterol is oxidised by cholesterol 
oxidase to yield hydrogen peroxide and ketones. The hydrogen peroxide reacts with 10-acetyl-3, 7-
dihydroxyphenoxazine (Amplex Red reagent) to produce highly fluorescent resorufin, which is 
measured by excitation at 530 nm and emission detection at 590 nm. Each experiment contained a dose-
response of cholesterol standards and solvent only controls. Cholesterol concentrations of samples were 
calculated by reference to the cholesterol standards.  
Activated cPLA2 ELISA/Prostaglandin (PG)E2 ELISA - The activation of cPLA2 is accompanied by 
phosphorylation of the 505 serine residue creating an epitope that can be measured by ELISA as 
described (Bate et al., 2010). Briefly, maxisorb immunoplates were coated with 0.5 µg/ml of the mouse 
mAb anti-cPLA2, clone CH-7 (Upstate) and blocked with 5% milk powder. Samples were incubated 
for 1 hour and the amount of bound activated cPLA2 was detected using a rabbit polyclonal anti-
phospho-cPLA2 (Cell Signalling Technology), followed by biotinylated anti-rabbit IgG, extravidin-
alkaline phosphatase and 1 mg/ml 4-nitrophenyl phosphate solution. Absorbance was measured at 405 
nm and the amounts of activated cPLA2 present were expressed as “units activated cPLA2” where 1 unit 
was defined as the amount of activated cPLA2 in control samples. The amounts of PGE2 in 
synaptosomes were determined using a competitive enzyme immunoassay kit (R&D Systems, 
Abingdon, UK) according to the manufacturer's instructions.    
 
Brain extracts – Soluble extracts were prepared from the brains (frontal cortex) of Alzheimer’s patients 
(Asterand) using an adapted methodology of that previously described (Shankar et al., 2008). Briefly, 
brain tissue was cut into small pieces and approximately 100 mg was added to 2 ml tubes containing 
lysing matrix D beads (Q-Bio). Ice cold 20 mM Tris, pH 7.4 containing 150 mM NaCl was added to an 
equivalent of 100 mg brain tissue/ml, tubes were shaken for 10 minutes (Disruptor genie, Scientific 
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Instruments). This process was performed 3 times before tubes were centrifuged at 16,000 x g for 10 
minutes to remove particulate matter. Soluble material was prepared by passage through a 50 kDa filter 
(Sartorius) (16,000 x g for 30 minutes to remove proteolytic enzymes, membrane-bound and larger 
forms of Aβ. The remaining material was then desalted (3 kDa filter (Sartorius)) to eliminate bioactive 
small molecules and drugs and the retained material collected (preparation contains molecules with 
molecular weights between 3 and 50 kDa). One of the reasons that “natural Aβ” preparations were used 
in this study was that natural Aβ oligomers and monomers (unlike synthetic peptides) are stable (Jin et 
al., 2011; Shankar et al., 2008; Walsh et al., 2002). For example, after Aβ monomers had been incubated 
for 7 days at 37oC in a cell free system we did not find any Aβ oligomers. Brain extracts were not 
pooled, rather monomers and oligomers were isolated from 3 main brain extracts and each were 
measured in triplicate. 
Monomer and Oligomer preparations – Monomer preparations were prepared by passage through a 
10 kDa filter (Sartorius). In theory Aβ dimers have a molecular weight of 9 kDa and should pass through 
the 10 kDa filter. However, natural Aβ is bound to membrane components that increase the molecular 
weight of Aβ dimers and consequently no Aβ dimers were detected in 10 kDa filtrates. It should be 
noted that Aβ monomer preparations contained Aβ40 and Aβ42 (confirmed by end-specific ELISA, see 
below) and other small APP fragments.  Oligomer preparations were collected from the retained 
material following a 10 kDa filtration (10 to 50 kDa), For monomer-depleted brain extracts 1 ml samples 
were centrifuged in a 10 kDa filter and the retained material diluted back to 1 ml with culture medium.  
Size exclusion chromatography was performed on samples using a Superdex 75 PC column (separates 
peptides ranging from 3 kDa to 70 kDa) (GE Healthcare) with an elution rate of 0.2 ml/minute. 
Preparations were stored at -80oC. For cell experiments preparations were diluted in neurobasal medium 
containing B27 components. For immunoblots, preparations were mixed with an equal volume of 0.5% 
NP-40, 5 mM CHAPS, 50 mM Tris, pH 7.4 and separated by gel electrophoresis. Proteins were 
transferred onto a Hybond-P polyvinylidiene fluoride membrane by semi-dry blotting and blocked using 
10% milk powder. Aβ was detected by incubation with mAb 6E10, reactive with amino acids 1-16 of 
human Aβ (Covance), biotinylated anti-mouse IgG, extravidin-peroxidase and enhanced 
chemiluminescence. 
Immunodepletions - Brain extracts or monomer preparations were incubated with 1 μg/ml mAb 6E10 
(reactive with amino acids 1-16, Covance) or an isotype control (mock-depletion) and incubated at 4oC 
on rollers for 24 hours. Protein G microbeads were added (10 µl/ml) (Sigma) for 2 hours and protein G 
bound-antibody complexes removed by centrifugation. The depleted media was passed through a 50 
kDa filter before further use.  
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Sample preparation for Aβ40/Aβ42 ELISA – To detach Aβ42 from membrane components that blocked 
specific epitopes samples (300 µl) were mixed with 700 µl of propan-2-ol and sonicated. Proteins were 
precipitated by adding 250 µls 100%w/v trichloroacetic acid, incubating on ice for 30 mins and 
centrifugation (16,000 x g for 10 mins at 4oC). The pellet was washed twice with ice cold acetone, 
suspended, first in 1% NH4OH and then in a buffer containing 150 mM NaCl, 10 mM Tris-HCl, pH 
7.4, 10 mM EDTA, 0.2% SDS and sonicated. 
 
Aβ40/Aβ42 ELISA - Nunc Maxisorb immunoplates were coated with mAb 4G8 (epitope 17-24) 
(Covance) and blocked with 5% milk powder. Samples were added for 1 hour. In separate plates, Aβ40 
was detected with rabbit polyclonal PC-149 (Merck) and Aβ42 with a rabbit mAb BA3-9 (Covance), 
followed by biotinylated anti-rabbit IgG, extravidin alkaline phosphatase (Sigma) and 1 mg/ml 4-
nitrophenol phosphate solution. Absorbance was measured at 405 nm and compared to a dose response 
of synthetic Aβ1-40/Aβ1-42 (Bachem) suspended in the sample preparation buffer (as above) and 
sonicated. 
PrPC filtration assays – Soluble PrPC was isolated from neuronal membrane preparations by a process 
including digestion with 0.2 units of phosphatidylinositol-phospholipase C (Sigma) followed by 
immunoaffinity and reverse phase chromatography on C18 columns as described (Bate and Williams, 
2011). 1 nM soluble PrPC was incubated with Aβ monomers or Aβ oligomers for 1 hour and then 
centrifuged through 50 kDa filters (Vivaspin - Sartorius) (Bate and Williams, 2011). The filtrate was 
collected and tested for the presence of PrPC by ELISA. 
 
PrPC ELISA - The amount of PrPC in samples was determined by ELISA as described (Bate and 
Williams, 2011). Maxisorb immunoplates were coated with mAb ICSM18 (Dr M. Tayebi). Samples 
were added and PrP was detected with biotinylated mAb ICSM35 (Dr M. Tayebi) followed by 
extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenyl phosphate (Sigma). Absorbance was 
measured on a microplate reader at 405 nm and the amount of PrP in samples was calculated by 
reference to a standard curve of recombinant murine PrP (Prionics).  
 
Preparation of Fab fragments – Fab (fraction antigen-binding) fragments were prepared from mAb 
4F2 with the Immunopure Fab preparation Kit (Pierce) using immobilised papain using the 
manufacturer’s instructions.  
Statistical Analysis - Comparison of treatment effects was carried out using Student’s paired t-tests, 
one-way and two-way ANOVA with Bonferroni’s post-hoc tests (IBM SPSS statistics 20). Error values 
reported are standard deviation (SD) and significance was determined where P<0.01. Correlations 
between data sets were analysed using Pearson’s bivariate coefficient (IBM SPSS statistics 20). 
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Results 
 
Aβ caused synapse damage in cultured neurons - Since the loss of synaptic proteins is a feature of 
AD that strongly correlates with cognitive decline (Counts et al., 2006; Masliah et al., 1991; Reddy et 
al., 2005) the effect of Aβ on the amounts of synaptic proteins in cultured neurons was studied. A 
soluble brain extract from an AD patient contained forms of Aβ including monomers, dimers and 
trimers (Figure 1A). The addition of brain extract caused the loss of synaptophysin, CSP, synapsin-1 
and vesicle-associated membrane protein (VAMP)-1, from neurons indicative of synapse degeneration 
(Figure 1B). However, there was no loss of caveolin from treated neurons, nor was there any reduction 
in cell viability (98% survival ± 5 compared with 100% survival ± 6, n=0, P=0.45), indicating synapse 
degeneration without significant neuronal death. Immunodepletion with monoclonal antibody (mAb) 
6E10 (reactive with Aβ, amino acids 1-16) reduced the concentrations of both Aβ40 (7.44 nM ± 0.8 SD 
to 0.5 nM ± 0.4 nM) and Aβ42 (1.21 nM ± 0.16 to 0.16 nM ± 0.09 nM) in brain extracts, whereas mock-
depletion had no significant effect on Aβ40 (7.44 nM ± 0.8 to 7.12 nM ± 0.65 nM) or Aβ42 (1.21 nM ± 
0.22 to 1.09 nM ± 0.29 nM). The Aβ-depleted brain extract still contained other peptides as shown by 
a coomassie blue stain (supplementary Figure 1). The addition of brain extracts to neurons resulted in 
the dose-dependent loss of synaptophysin (Figure 1C) and CSP (Figure 1D) (Bate and Williams, 2011). 
The addition of a brain extract that had been depleted of Aβ did not affect the amounts of synaptophysin 
or CSP in neurons; observations consistent with the hypothesis that Aβ is a major neurotoxin that causes 
synapse damage. A cautionary note that the 6E10 antibody used in these depletions reacts with an 
epitope common to multiple APP breakdown fragments including Aβ40, Aβ42 and other carboxy-
terminal fragments of APP (Hunter and Brayne, 2017). 
 
Removal of Aβ monomers increased the brain extract-induced synapse damage – Brain extracts 
from AD patients contain a mixture of Aβ monomers and soluble Aβ oligomers, predominantly dimers 
and trimers (Klyubin et al., 2008; Mc Donald et al., 2010; Shankar et al., 2008). Aβ oligomers were 
prepared by passage of the extract through a 10 kDa filter; the retained material contained Aβ oligomers 
but lacked smaller APP fragments that we have called Aβ monomers (Figure 2C, lane 2). Brain extracts 
depleted of Aβ monomers caused more synapse damage, as measured by the loss of synaptophysin 
(Figure 2A) and CSP (Figure 2B), when compared with the original brain extracts that contained Aβ 
monomers (Figure 2C, lane 1). To ensure that this observation was repeatable another 8 soluble brain 
extracts were depleted of monomers. In each sample the monomer-depleted extract caused significantly 
more synapse damage, as measured by the loss of synaptophysin, than did the untreated brain extracts 
(Figure 2D). The concentrations of Aβ40 and Aβ42 varied between different samples. As there was a 
close correlation between Aβ42 concentrations and synapse damage, whereas there was a poorer 
correlation between Aβ40 and effect, we chose to quantify brain extracts on their Aβ42 content. In the 
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following experiments brain extracts were not pooled, rather monomers and oligomers were isolated 
from 3 main extracts and these were each measured in triplicate. 
 
Aβ monomers did not cause synapse damage – Aβ monomers were prepared by passing brain extracts 
through a 10 kDa filter.  This preparation contained only Aβ monomers (Figure 3A, lane 2) which eluted 
in a single peak from a Superdex 75 PC column (Figure 3B). The addition of Aβ monomer preparations 
containing 1 nM Aβ42 did not affect the amounts of synaptophysin (Figure 3C) or CSP (Figure 3D) in 
neurons. In another experiment the addition of concentrated monomer preparations containing 20 nM 
Aβ42 did not cause a significant reduction in the amounts of synaptophysin in neurons (98.4 units 
synaptophysin ± 3.5 compared with 100 units ± 3.8, n=12, P=0.34). In contrast, Aβ oligomers caused 
the loss of synaptophysin and CSP from neurons in a dose-dependent manner; there was a 50% 
reduction in synaptic proteins in neurons incubated with 0.2 nM Aβ42 oligomers. 
 
Aβ oligomers but not monomers inhibit synaptic vesicle recycling - The uptake of fluorescent FM1-
42 into recycling synaptic vesicles is commonly used to study synapse function (Klingauf et al., 1998). 
The addition of ionomycin for 1 minute increased the amounts of FM1-43 taken up by synaptosomes 
in a dose-dependent manner (Figure 4A). The addition of Aβ inhibited the uptake of FM1-43 suggesting 
it inhibited synaptic vesicle recycling (Parodi et al., 2010). In the current study the ionomycin-induced 
uptake of FM1-43 into synaptosomes was reduced by incubation with brain extract (Figure 4B). 
Immunodepletion studies showed that Aβ was responsible for the inhibition of ionomycin-induced 
FM1-43 uptake by brain extract. The effects of brain extracts on the suppression of FM1-43 uptake 
were increased after the removal of monomers (Figure 4C). Aβ oligomers, but not Aβ monomer 
preparations caused a dose-dependent inhibition of the ionomycin-induced uptake of FM1-43 (Figure 
4D).  
 
Aβ monomers inhibited Aβ oligomer-induced synapse damage – The hypothesis that Aβ monomers 
protected synapses was tested. Pre-treatment with monomer preparations (containing 5 nM Aβ42, 
approximately 5 times the concentration of Aβ oligomers that caused maximum synapse damage (1 
nM)) protected neurons against the loss of synaptophysin (Figure 5A) and CSP (Figure 5B) triggered 
by Aβ oligomers. The protective effect of monomers was stimulus specific; pre-treatment of neurons 
with monomers (containing 5 nM Aβ42) did not alter the loss of synaptophysin from neurons incubated 
with phospholipase A2-activating peptide (PLAP), a peptide known to cause synapse damage (Bate et 
al., 2010) (Figure 5C). Immunodepletion studies were used to examine the nature of the neuroprotective 
moiety in the monomer preparations. Immunodepletion with mAb 6E10 (reactive with Aβ, amino acids 
1-16) reduced the concentrations of Aβ42 (from 5 nM ± 0.2 to 0.1 nM ± 0.1 nM, n=12, P<0.01) whereas 
mock-depletion had no significant effect (5 nM ± 0.2 compared with 4.9 nM ± 0.3 nM, n=12, P=0.27). 
Neurons pre-treated with the Aβ-depleted monomer preparations were not protected against synapse 
 11 
damage caused by Aβ oligomers (containing 0.5 nM Aβ42) (Figure 5D). Pre-treatment with monomer 
preparations caused a dose-dependent inhibition of synapse damage when neurons were incubated with 
an oligomer preparation containing 0.5 nM Aβ42 (Figure 5E).  
 
Aβ monomers inhibited Aβ oligomer-induced activation of cPLA2 in synapses – Aberrant activation 
of cPLA2 is thought to trigger synapse damage based on observations that Aβ42 activates cPLA2 (Anfuso 
et al., 2004; Shelat et al., 2008), that pharmacological inhibition of cPLA2 protected cultured neurons 
against Aβ-induced synapse damage (Bate et al., 2010) and ameliorated cognitive decline in a mouse 
model of AD (Sanchez-Mejia et al., 2008). For these reasons the effects of brain extracts upon cPLA2 
in synapses were examined. The addition of brain extracts containing 1 nM Aβ42 increased the amounts 
of activated cPLA2 found in synaptosomes (Figure 6A) whereas brain extracts depleted of Aβ had a 
reduced effect. Aβ oligomers, but not Aβ monomers, activated synaptic cPLA2 (Figure 6B). Pre-
treatment of synaptosomes with monomer preparations (containing 1 nM Aβ42, approximately 5 times 
the concentration of Aβ oligomers that caused maximum activation of cPLA2 (0.2 nM)) reduced the 
activation of cPLA2 by Aβ oligomers (Figure 6C) but not by PLAP (Figure 6D) indicating that 
monomers did not have a direct effect upon this enzyme. Immunodepletion studies demonstrated that it 
was Aβ within the monomer preparations that was responsible for blocking the Aβ oligomer-induced 
activation of synaptic cPLA2 (Figure 6E) and the production of prostaglandin (PG)E2 (Figure 6F), a 
bioactive lipid found in high concentrations the brains of AD patients (Montine et al., 1999) which 
causes synapse degeneration in cultured neurons (Bate et al., 2010). Collectively these results suggest 
that it is Aβ monomers that inhibit the Aβ oligomer-induced activation of synaptic cPLA2 and PGE2 
production.  
 
Aβ monomers inhibited the Aβ oligomer-induced increase in cholesterol concentrations - The 
concentrations of cholesterol in cell membranes is a critical factor involved in neurodegeneration 
(Maxfield and Tabas, 2005). The addition of brain extracts significantly increased the concentrations of 
cholesterol in synaptosomes (West et al., 2017) (Figure 7A) an observation that is consistent with 
reports of increased cholesterol in Aβ positive synapses in the cortex of Alzheimer’s patients (Gylys et 
al., 2007). This effect of brain extracts was lost after the removal of Aβ. Further studies showed that Aβ 
oligomers increased synaptic cholesterol while monomers did not (Figure 7B). When incubated with 
brain extracts containing between 1 and 0.06 nM Aβ42 there were significant correlations between 
concentrations of cholesterol and activated cPLA2 (Figure 7C) and PGE2 (Figure 7D). Next, the effects 
of Aβ monomers on the Aβ oligomer-induced increase in synaptic cholesterol concentrations were 
studied. Monomer preparations (containing 5 nM Aβ42) blocked the increase in cholesterol 
concentrations caused by Aβ oligomers (containing 0.5 nM Aβ42) (Figure 7E). Immunodepletion studies 
showed that Aβ monomers were responsible for blocking the Aβ oligomer-induced increase in 
cholesterol.   
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Aβ monomers inhibited Aβ oligomer-induced aggregation of PrPC – The observations that cross-
linkage of PrPC by antibodies leads to neurodegeneration (Solforosi et al., 2004) and that Aβ oligomers 
cause PrPC aggregation (Bate and Williams, 2011) suggested that aggregation of PrPC is a critical factor 
that initiates synapse damage and the pathogenesis of AD. Here we show that PrPC incubated with brain 
extract formed complexes containing at least two PrPC molecules as shown by immunoblot (Figure 8A). 
This qualitative study was supported by quantitative studies in which 1 nM soluble PrPC was passed 
through a 50 kDa filter as described (Bate and Williams, 2011). Although PrPC has a molecular weight 
that is dependent upon glycosylation it does not exceed 37 kDa and consequently all soluble PrPC passed 
through a 50 kDa filter. PrPC incubated with Aβ monomers (1 nM Aβ42) also passed through a 50 kDa 
filter whereas incubation with Aβ oligomers (1 nM Aβ42) reduced the amounts of PrPC that passed 
through a 50 kDa filter by approximately 80%. The formation of PrPC complexes of greater than 50 
kDa was lost after the removal of Aβ from brain extracts (Figure 8B) indicating that Aβ oligomers 
cross-link PrPC.  To test the hypothesis that the binding of Aβ monomers to PrPC block the aggregation 
of PrPC by Aβ oligomers, soluble PrPC was pre-treated with monomers (containing  1 nM Aβ42) and 
incubated with oligomers (containing 1 nM Aβ42). Pre-treatment of soluble PrPC with Aβ monomers 
significantly reduced the Aβ oligomer-induced formation of PrPC complexes greater than 50 kDa 
(Figure 8C).  
 
Fab fragments block the mAb-mediated cross-linkage of PrPC and synapse damage – The cross-
linkage of PrPC by mAbs caused neurodegeneration in vivo (Solforosi et al., 2004) and synapse damage 
in cultured neurons (Bate and Williams, 2011). The PrPC-reactive mAb 4F2 mimicked some of the 
effects of Aβ oligomers on synaptosomes, including increasing cholesterol concentrations (Figure 9A) 
and activating cPLA2 (Figure 9B). These effects were not seen in synaptosomes incubated with 
monovalent Fab fragments derived from 4F2 that do not cross-link PrPC. When the mAb/Fab fragments 
were incubated with cultured neurons, the divalent mAb 4F2 caused a dose-dependent loss of 
synaptophysin (Figure 9C) and CSP (Figure 9D) which was not seen with the monovalent Fab 
fragments. Pre-treatment of synaptosomes with Fab fragments from 4F2 (but not Fab fragments 
prepared from a control mouse IgG mAb) significantly reduced the mAb 4F2-induced increase in 
cholesterol concentrations (Figure 10A) and the mAb 4F2-induced activation of cPLA2 (Figure 10B). 
Pre-treatment of neurons with 4F2 Fab fragments, but not Fab fragments from a control IgG, also 
reduced the mAb 4F2-induced reduction of synaptophysin (Figure 10C) and CSP (Figure 10D) from 
neurons. 
 
Discussion 
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The principal finding of this study is that Aβ monomer preparations reduced the Aβ oligomer-induced 
synapse damage. This protection was associated with Aβ monomers reducing the Aβ oligomer-induced 
aggregation of PrPC and the subsequent increase in synaptic cholesterol concentrations and the 
activation of cPLA2. 
 
Soluble brain extracts were used in this study since they contain a mixture of monomers and low-n 
oligomers, that are similar in size, solubility, stability and potency to the Aβ previously reported in the 
CSF from AD patients (Bibl et al., 2007; McLean et al., 1999; Mehta et al., 2000). Thus, the presence 
of brain extracts containing picomolar concentrations of Aβ42 caused synapse damage to cultured 
neurons. The initial observations, that the removal of Aβ monomers from brain extracts increased 
synapse damage, suggested that Aβ monomers have a protective role. This hypothesis was supported 
by experiments using Aβ monomers collected by filtration. At the maximum concentration of 
monomers used (containing 20 nM Aβ42) they did not cause synapse damage. In contrast, the oligomer 
preparation that reduced the synaptophysin content of neurons by 50% contained approximately 0.2 nM 
Aβ42 (Figure 3C). We note that in addition to Aβ40 and Aβ42 the preparations used in this study are likely 
to contain other APP fragments which may contribute to the activity reported and consequently the 
word “monomers” was used to include all Aβ fragments passing through a 10 kDa filter. The activity 
of monomer preparations was removed by immunodepletion with mAb 6E10, indicating that the 
bioactive peptides contained a specific epitope. However the methods used in this study do not 
differentiate whether those peptides were Aβ40, Aβ42 or other APP fragments sharing this epitope. 
 
Recent studies suggest that Aβ caused synapse damage as a consequence of aberrant cell signaling. As 
synthetic Aβ42 monomers activate the phosphatidylinositol-3-kinase pathway (Giuffrida et al., 2009) 
and insulin signalling (Giuffrida et al., 2012) it is possible that Aβ monomers and Aβ oligomers activate 
different signalling pathways. Here we show that the Aβ oligomers, but not Aβ monomers, activate 
cPLA2 in synaptosomes, consistent with reports that pharmacological inhibition of cPLA2 protected 
cultured neurons against Aβ-induced synapse damage (Bate et al., 2010) and ameliorated cognitive 
decline in a mouse model of AD (Sanchez-Mejia et al., 2008). The activation of cPLA2 by Aβ involves 
the translocation of cPLA2 to lipid rafts and is sensitive to cholesterol depletion (Bate and Williams, 
2011). Here we demonstrate that Aβ oligomers, but not Aβ monomers, increased cholesterol 
concentrations and activated cPLA2 within synapses.  
 
PrPC that is highly expressed at synapses (Brown, 2001; Herms et al., 1999) has been identified as a 
receptor for Aβ42 (Balducci et al., 2010; Lauren et al., 2009) and the activation of cPLA2 in synapses by 
Aβ involves PrPC (Bate and Williams, 2011). PrPC is attached to membranes via a 
glycosylphosphatidylinositol (GPI) anchor (Stahl et al., 1987) and the cross-linkage of GPI-anchored 
proteins leads to membrane realignment and cell activation (Chen et al., 2006; Suzuki et al., 2007). 
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More specifically, the antibody-mediated cross-linkage of PrPC promotes the formation of lipid rafts 
and cell signalling in T cells (Stuermer et al., 2004). Raft formation is associated with the 
oligomerization of proteins (Engelman, 2005), specifically GPI-anchored proteins (Eggeling et al., 
2009; Suzuki et al., 2012), as the aggregation of membrane components leads to the reorganization of 
cell membranes (Hammond et al., 2005; Lingwood et al., 2008). We hypothesise that it is the 
aggregation of PrPC caused by Aβ oligomers that is an essential process leading to synapse damage. 
Activation of cell signalling pathways is associated with the aggregation of proteins (Suzuki et al., 2007) 
and here we show that Aβ oligomers, but not monomers, cause PrPC to aggregate, increase synaptic 
cholesterol concentrations and activate cPLA2. This hypothesis is supported by our observations that 
the cross-linkage of PrPC by mAb 4F2 mimicked some of the effects of Aβ oligomers upon 
synaptosomes, including increasing cholesterol concentrations and activating cPLA2; mAb 4F2 also 
caused synapse degeneration in cultured neurons. In contrast, no changes in synaptic cholesterol 
concentrations, activation of cPLA2 or synapse damage were observed in synaptosomes or neurons 
incubated with monovalent Fab fragments derived from mAb 4F2. The reorganisation of rafts in the 
outer leaflet, in response to stimuli, results in the sorting of intracellular signalling molecules on the 
inner, cytoplasmic leaflet (Eisenberg et al., 2006; Hunter, 2000). Thus, the clustering of individual rafts 
exposes proteins to new membrane environments and can initiate signalling. Consequently the 
aggregation of cell surface PrPC can cause the clustering of receptor-associated signalling molecules 
including cPLA2 within lipid raft platforms. It should be noted that Aβ has been reported to bind to 
numerous other proteins (Jarosz-Griffiths et al., 2016) meaning that Aβ oligomers have the potential to 
link PrPC with other proteins. The heterogeneity of complexes formed between Aβ oligomers and 
numerous different “receptors” may help to explain how Aβ causes the wide variety of cellular 
responses reported. 
 
We report that Aβ monomer preparations protected neurons against the Aβ oligomer-induced synapse 
damage. These monomers also reduced the Aβ oligomer-induced increase in synaptic cholesterol 
concentrations and activation of cPLA2 that is closely associated with synapse damage. Aβ monomers 
did not affect the activation of cPLA2 by PLAP, nor did they affect PLAP-induced synapse damage, 
indicating that they interfere with a stimulus-specific pathway. Aβ monomers did not cause aggregation 
of PrPC, consistent with the hypothesis that Aβ contains a single PrPC-binding site and consequently Aβ 
oligomers, but not Aβ monomers cause the aggregation of PrPC. The presence of Aβ monomers blocks 
the Aβ oligomer-induced aggregation of PrPC which has been shown to cause cell signalling and 
synapse degeneration (Bate and Williams, 2012). These results contrast studies that showed that 
synthetic Aβ42 monomers did not bind to recombinant PrP23-231 (Freir et al., 2011; Nicoll et al., 2013; 
Um et al., 2012) and suggest that the difference may be the sources of Aβ and PrP proteins used in 
binding assays (synthetic vs natural). This study also used natural rather than recombinant PrP proteins. 
The post-translational modifications of PrP include a GPI anchor and N-linked glycosylation, factors 
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which can affect structure and function of some proteins (Butikofer et al., 2001; Elfrink et al., 2008; 
Kemble et al., 1993). For example, native PrPC contains sialic acid (Rudd et al., 2001; Stahl et al., 1992) 
a glycan implicated in Aβ binding and structure (Hong et al., 2014; Kakio et al., 2002). 
 
Critically we found that pre-treatment with Aβ monomer preparations prevented the Aβ oligomer-
induced aggregation of PrPC. These preparations contain a mixture of Aβ species and consequently it 
was not possible to identify the precise form of Aβ that is responsible for this effect. It is possible that 
more than one Aβ species is involved. We hypothesise that Aβ monomers compete with Aβ oligomers 
for binding sites on PrPC. Thus, the binding of Aβ monomers to PrPC prevented the binding of Aβ 
oligomers and subsequent cross-linkage of PrPC. This hypothesis is supported by studies using Fab 
fragments of the PrPC-binding mAb 4F2. Pre-treatment of synaptosomes with monovalent Fab 
fragments of 4F2 (that do not cross-link PrPC) significantly reduced both mAb 4F2-induced increase in 
cholesterol concentrations and mAb 4F2-induced activation of cPLA2. Furthermore, pre-treatment of 
neurons with 4F2 Fab fragments blocked the mAb 4F2-induced synapse damage. 
 
Factors thought to be involved in determining synapse damage in AD include the length of the Aβ 
fragment, oligomer size and the conformation of Aβ. Although many studies measure Aβ levels as a 
marker of disease progression, they often do not differentiate between Aβ monomers and oligomers. 
These results suggest that the concentration of Aβ monomers is another factor that should be considered 
in determining disease progression. Thus, the presence of high concentrations of Aβ monomers could 
protect neurons against synapse damage even in the presence of high concentrations of Aβ oligomers. 
However, the role of Aβ monomers is not completely clear as others have reported that the presence of 
Aβ monomers was associated with dementia (Mc Donald et al., 2010). It should be noted that this work 
was carried out using human brain-derived Aβ preparations incubated with mouse synaptosomes and 
neurons. Practicalities prevented the ideal situation which would have been to use human neurons to 
reduce variation occurring from cross species experiments. 
 
Conclusions  
 
In conclusion these results support the hypothesis that Aβ monomers have a protective role by reducing 
synapse damage caused by Aβ oligomers. They are consistent with the hypothesis that Aβ monomers 
compete with Aβ oligomers for binding sites on PrPC and that the binding of Aβ monomers prevents 
the Aβ oligomer-induced aggregation of PrPC that triggers aberrant activation of cPLA2 and synapse 
damage. These observations suggest that AD may develop as a result of changes in the Aβ 
monomer:oligomer ratio. 
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Figure 1 – Soluble brain extracts caused Aβ-dependent synapse damage – (A) Western blot showing 
forms of Aβ including monomers (M), dimers (D) and trimers (T) contained within a soluble brain extract. 
(B) Western blots showing the amounts of synaptophysin, CSP, synapsin-1, VAMP-1 and caveolin in 
cultured neurons that had been incubated with brain extract as shown. The amounts of synaptophysin (C) 
and CSP (D) neurons incubated with brain extract (■), Aβ-depleted brain extract () or mock-depleted 
brain extract () as shown for 24 hours. Values are means ± SD from triplicate experiments performed 4 
times, n=12. Some data points representing mock depleted brain extract () in (C) and (D) are not visible 
on the graphs as they are overlaid by data points representing the normal brain extract (■).  
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Figure 2 – Removal of Aβ monomers from brain extracts increases synapse damage – The amounts of 
synaptophysin (A) and CSP (B) in neurons incubated with soluble brain extract (■) or monomer-depleted 
brain extract (□) as shown. Values are means ± SD from triplicate experiments performed 4 times, n=12.  
(C) Immunoblot showing Aβ monomers (M), dimers (D) and trimers (T) contained within brain extract (1) 
and brain extract retained by a 10 kDa filter (Aβ oligomers) (2) separated by gel electrophoresis.  (D) The 
amounts of synaptophysin in neurons incubated with 8 brain extracts (10 ng/ml) (■) or the same brain 
extracts that had been depleted of monomers (□). Values are means ± SD from triplicate experiments 
performed twice, n=6. 
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Figure 3 – Aβ monomers do not cause synapse damage - (A) Immunoblot showing forms of Aβ including 
monomers (M), dimers (D) and trimers (T) in soluble brain extract (1) and brain extract passed through a 
10 kDa filter (Aβ monomers) (2). (B) The concentrations of Aβ in fractions eluted from a Superdex 75 PC 
column injected with a brain extract monomer preparation. Values are means of duplicates. The amounts 
of synaptophysin (C) and CSP (D) in neurons incubated with monomers (○) or oligomers (●) containing 
Aβ42 as shown (0.0625, 0.125, 0.25, 0.5 and 1 nM). Values are means ± SD from triplicate experiments 
performed 3 times, n=9.  
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Figure 4 – Aβ oligomers inhibit synaptic vesicle recycling – (A) The amounts of FM1-43 in 
synaptosomes incubated with ionomycin as shown (●). Values are mean % fluorescence (100% = maximum 
fluorescence) ± SD from triplicate experiments performed 3 times (n=9). (B) The amounts of FM1-43 in 
synaptosomes incubated with control medium (□), brain extract, Aβ-depleted brain extract or mock-
depleted brain extract (■) for 30 minutes and incubated with 1 μM ionomycin. Values are means ± SD from 
triplicate experiments performed 3 times (n=9). *=fluorescence significantly less than controls. (C) The 
amounts of FM1-43 in synaptosomes incubated with brain extract (●) or monomer-depleted brain extract 
(□) for 30 minutes and incubated with 1 μM ionomycin. Values are means ± SD from triplicate experiments 
performed 3 times (n=9). (D) The amounts of FM1-43 in synaptosomes incubated with oligomer (●) or 
monomer (○) preparations containing Aβ42 for 30 minutes as shown and incubated with 1 μM ionomycin. 
Values are means ± SD from triplicate experiments performed 3 times (n=9).  
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Figure 5 - Aβ monomers inhibit Aβ oligomer-induced synapse damage - The amounts of synaptophysin 
(A) and CSP (B) in neurons pre-treated with control medium (●) or monomers (containing 5 nM Aβ42) (○) 
and incubated with Aβ oligomers as shown. Values are means ± SD from triplicate experiments performed 
3 times, n=9. (C) The amounts of synaptophysin in neurons pre-treated with control medium (●) or 
monomer preparations containing 5 nM Aβ42 (○) and incubated with PLAP. Values are means ± SD from 
triplicate experiments performed 3 times, n=9. (D) The amounts of synaptophysin in neurons pre-treated 
with control medium (■), monomers (□), Aβ-depleted monomers (striped bar) or mock-depleted monomers 
(hatched bar) and incubated with an oligomer preparation containing 0.5 nM Aβ42. Values are means ± SD 
from triplicate experiments performed 3 times, n=9. (E) The amounts of synaptophysin in neurons pre-
treated with monomers containing Aβ42 as shown (●) and incubated with an oligomer preparation 
containing 0.5 nM Aβ42. Values are means ± SD from triplicate experiments performed 2 times, n=6.  
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Figure 6 - Aβ monomers inhibit the Aβ oligomer-induced activation of synaptic cPLA2 - (A) The 
amounts of activated cPLA2 in synaptosomes incubated with control medium (□) brain extract (■), Aβ-
depleted brain extract (striped bar) or mock-depleted brain extract (hatched bar). Values are means ± SD 
from triplicate experiments performed 3 times, n=9. (B) The amounts of activated cPLA2 in synaptosomes 
incubated with oligomers (●) or monomers (○) containing Aβ42 as shown. Values are means ± SD from 
triplicate experiments performed 3 times, n=9. The amounts of activated cPLA2 in synaptosomes pre-treated 
with control medium (●) or monomers containing 1 nM Aβ42 (○) and incubated with oligomers containing 
Aβ42 (C) or PLAP (D) as shown. Values are means ± SD from triplicate experiments performed 3 times, 
n=9. The amounts of activated cPLA2 (E) and PGE2 (F) in synaptosomes pre-treated with control medium 
(■), monomers containing 1 nM Aβ42 (□), Aβ-depleted monomers (striped bars) or mock-depleted 
monomers (hatched bars) and incubated with oligomers containing 0.5 nM Aβ42.Values are means ± SD 
from triplicate experiments performed 3 times, n=9.    
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Figure 7. Aβ monomers inhibit the Aβ oligomer-induced increase in synaptic cholesterol - (A) The 
concentrations of cholesterol in synaptosomes incubated with control medium (□) brain extract (■), Aβ-
depleted brain extract (striped bar) or mock-depleted brain extract (hatched bar). Values are means ± SD 
from triplicate experiments performed 3 times, n=9. (B) The concentrations of cholesterol in synaptosomes 
incubated with oligomers (●) or monomers (○) containing Aβ42 as shown. Values are means ± SD from 
triplicate experiments performed 3 times, n=9. In synaptosomes incubated with oligomers containing 
between 0.06 and 1 nM Aβ42 there were significant correlations between the concentrations of cholesterol 
and the amounts of activated cPLA2 (C), Pearson’s coefficient=0.75,  p <0.01 and the concentrations of 
PGE2 produced (D) Pearson’s coefficient= 0.79,  p<0.01. (E) The concentrations of cholesterol in 
synaptosomes pre-treated with control medium (■), monomers (□), Aβ-depleted monomers (striped bar) or 
mock-depleted monomers (hatched bar) and incubated with oligomers containing 0.5 nM Aβ42. Values are 
means ± SD from triplicate experiments performed 3 times (n=9).  
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Figure 8 - Aβ oligomers cause aggregation of PrPC – (A) Immunoblot showing PrPC in preparations of 
(1) (1) PrPC or (2) PrPC mixed with Aβ oligomers separated by non-denaturing gel electrophoresis. (B) The 
concentrations of PrPC passing through a 50 kDa filter after incubation with control medium (checkerboard 
bar), monomers (□), oligomers (■) or Aβ-depleted oligomers (striped bars). Values are means from 
triplicate experiments performed 4 times, n=12. *= PrPC< 50kDa significantly less than in controls. (C) The 
concentrations of PrPC passing through a 50 kDa filter after PrPC was incubated with Aβ oligomers  mixed 
with control medium (■), monomers (□), Aβ-depleted monomers (striped bar) or mock-depleted monomers 
(hatched bars). Values are means ± SD from triplicate experiments performed 3 times, n=9. 
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Figure 9 – A PrPC mAb increases synaptic cholesterol, activates synaptic cPLA2 and triggers synapse 
damage – (A) The concentrations of cholesterol in synaptosomes treated with control medium (□), 1 nM 
mAb 4F2 (■) or 2 nM 4F2 Fab fragments (striped bar). Values are means ± SD from triplicate experiments 
performed 3 times (n=9). *=cholesterol significantly higher than in control synaptosomes. (B) The amounts 
of activated cPLA2 in synaptosomes treated with mAb 4F2 (●) or 4F2 Fab fragments (○) as shown. Values 
are means ± SD from triplicate experiments performed 3 times, n=9. (C) The amounts of synaptophysin in 
neurons treated with mAb 4F2 (●) or 4F2 Fab fragments (○). Values are means ± SD from triplicate 
experiments performed 3 times, n=9. (D) The amounts of CSP in neurons treated with mAb 4F2 (●) or 4F2 
Fab fragments (○). Values are means ± SD from triplicate experiments performed 3 times, n=9.  
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Figure 10 – Fab 4F2 fragments protect neurons against mAb 4F2-induced synapse damage – (A) The 
concentrations of cholesterol in synaptosomes incubated with 2 nM mAb 4F2 (■), or mixtures containing 
2 nM 4F2 Fab fragments and 2 nM mAb 4F2 (striped bar) or 2 nM control Fab fragments and 2 nM mAb 
4F2 (vertical striped bar). Values are means ± SD from triplicate experiments performed 3 times (n=9). 
*=cholesterol significantly lower than in synaptosomes incubated with mAb 4F2. (B) The amounts of 
activated cPLA2 in synaptosomes pre-treated with control medium (●), 2 nM 4F2 Fab fragments (□) or 2 
nM control IgG Fab fragments (■) and incubated with mAb 4F2. Values are means ± SD from triplicate 
experiments performed 3 times, n=9. The amounts of synaptophysin (C) and CSP (D) in neurons pre-treated 
with control medium (●), 2 nM 4F2 Fab fragments (□) or 2 nM control Fab fragments (■) and incubated 
with mAb 4F2. Values are means ± SD from triplicate experiments performed 3 times, n=9.  
 
 
